highly active antiretroviral therapy (HAART)
Jump to navigation
Jump to search
Introduction
Combinations of antiretroviral agents used in treatment of HIV1.
Indications
- retroviral infection
- HIV infection
- HIV1 infection
- HIV infection during pregnancy is always an indication for HAART
- HIV1 infection
- HIV infection
- race NOT a factor in treatment outcomes[2]
Dosage
- one antiretroviral protease inhibitor + 2 NRTI
- one NNRTI plus 2 NRTI
- three NRTIs
- two antiretroviral protease inhibitors + 2 NRTI[4]
zidovudine should be incorporated in all HAART regimens
do NOT use stavudine since combination of zidovudine & stavudine is contraindicated
high-dose multivitamin not helpful, perhaps harmful[5]
Adverse effects
- HAART may not be associated with better outcomes[1]
- immune reconstitution inflammatory syndrome
- paradoxical worsening of underlying opportunistic infection
- increased risk of cardiovascular disease[4]
More general terms
Additional terms
References
- ↑ 1.0 1.1 The Antiretroviral Therapy (ART) Cohort Collaboration. HIV treatment response and prognosis in Europe and North America in the first decade of highly active retroviral therapy. A collaborative analysis. Lancet 2006, 36:451 PMID: https://www.ncbi.nlm.nih.gov/pubmed/16890831
- ↑ 2.0 2.1 Silverberg MJ et al, Effectiveness of highly-active antiretroviral therapy by therapy by race/ethnicity. AIDS 2006, 20:1431 PMID: https://www.ncbi.nlm.nih.gov/pubmed/16847408
- ↑ Sackoff JE et al, Causes of death among persons with AIDS in the era of highly active antiretroviral therapy: New York City Ann Intern Med 2006, 145:397 PMID: https://www.ncbi.nlm.nih.gov/pubmed/16983127
Aberg JA The changing face of HIV care: Common things really are common. Ann Intern Med 2006, 145:463 PMID: https://www.ncbi.nlm.nih.gov/pubmed/16983135 - ↑ 4.0 4.1 4.2 Medical Knowledge Self Assessment Program (MKSAP) 14, 15 American College of Physicians, Philadelphia 2006, 2009
- ↑ 5.0 5.1 Isanaka S et al Effect of High-Dose vs Standard-Dose Multivitamin Supplementation at the Initiation of HAART on HIV Disease Progression and Mortality in Tanzania A Randomized Controlled Trial JAMA. 2012;308(15):1535-1544. <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/23073950 <Internet> http://jama.jamanetwork.com/article.aspx?articleid=1383231